María Paniagua-García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
María Paniagua-García has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- José Miguel Cisneros
Clinical Unit of Infectious Diseases, Microbiology and Parasitology, University Hospital Virgen del Rocío , Seville
3 shared publications - María Eugenia Pachón-Ibáñez
Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocío University Hospital / CSIC / University of Seville, Seville, Spain
3 shared publications - Elisa Cordero
Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital/CSIC/University of Seville, 41013 Seville, Spain
2 shared publications - Jerónimo Pachón
Department of Medicine, School of Medicine, University of Seville, Seville, Spain
2 shared publications Rocío Álvarez-Marín
Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Virgen del Rocío University Hospital, Seville, Spain
2 shared publicationsSonsoles Salto-Alejandre
2 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
Campylobacter spp Bloodstream Infections in Immunocompetent vs Immunodeficient Patients: A Multinational Cohort Study (2009–2024)
Background: Campylobacter spp bloodstream infections (BSIs) are an emerging clinical challenge, yet information on their clinical features remains limited. We aimed to evaluate their differential clinical characteristics and outcomes in immunocompetent (IC) and immunodeficient (ID) patients. Methods: A multicenter, multinational, retrospective cohort study of consecutive Campylobacter spp BSIs between 2009 and 2024 was carried out. Demographics, Charlson comorbidity index, types of immunodeficiencies, clinical characteristics, and antimicrobial susceptibility were analyzed. The primary outcomes were relapse or reinfection and death (all-cause mortality outcome). Results: A total of 261 episodes were included, 89 (34.1%) in IC and 172 (65.9%) in ID patients. Among the 172 ID patients, 104 (60.5%) and 68 (39.5%) had humoral or nonhumoral immunodeficiency (primary or secondary), and 42 (24.4%) had primary immunodeficiencies (PIDs). Patients with humoral immunodeficiency (humoral-ID patients) were younger (median age, 40 years [interquartile range, 23–66 years]), had lower Charlson comorbidity indexes (2 [1–5]), and had a higher frequency of previous Campylobacter spp infection. Resistance rates to fluoroquinolones (75%) and macrolides (14.5%) were high. BSI relapse or reinfection occurred in 21 (8.0%) patients, mostly humoral-ID patients (n = 19 [18.3%]), 11 (57.9%) of whom had PID. Death occurred with 30 days (all-cause mortality outcome) in 26 patients (9.9%) across the entire cohort; the 30-day mortality rate was lower in humoral-ID (n = 5 [4.8%]) than in IC (n = 12 [13.5%]; P = .05) patients. Conclusions: Humoral-ID patients and those with Campylobacter spp BSI were younger and had fewer comorbid conditions, and Campylobacter coli was the most frequent species. Relapse or reinfection was common in humoral-ID patients, particularly those with PID. The antimicrobial resistance in C coli and Campylobacter jejuni represents a clinical concern.
- 23 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
Open AccessCampylobacter spp Bloodstream Infections in Immunocompetent vs Immunodeficient Patients: A Multinational Cohort Study (2009–2024)
Background: Campylobacter spp bloodstream infections (BSIs) are an emerging clinical challenge, yet information on their clinical features remains limited. We aimed to evaluate their differential clinical characteristics and outcomes in immunocompetent (IC) and immunodeficient (ID) patients. Methods: A multicenter, multinational, retrospective cohort study of consecutive Campylobacter spp BSIs between 2009 and 2024 was carried out. Demographics, Charlson comorbidity index, types of immunodeficiencies, clinical characteristics, and antimicrobial susceptibility were analyzed. The primary outcomes were relapse or reinfection and death (all-cause mortality outcome). Results: A total of 261 episodes were included, 89 (34.1%) in IC and 172 (65.9%) in ID patients. Among the 172 ID patients, 104 (60.5%) and 68 (39.5%) had humoral or nonhumoral immunodeficiency (primary or secondary), and 42 (24.4%) had primary immunodeficiencies (PIDs). Patients with humoral immunodeficiency (humoral-ID patients) were younger (median age, 40 years [interquartile range, 23–66 years]), had lower Charlson comorbidity indexes (2 [1–5]), and had a higher frequency of previous Campylobacter spp infection. Resistance rates to fluoroquinolones (75%) and macrolides (14.5%) were high. BSI relapse or reinfection occurred in 21 (8.0%) patients, mostly humoral-ID patients (n = 19 [18.3%]), 11 (57.9%) of whom had PID. Death occurred with 30 days (all-cause mortality outcome) in 26 patients (9.9%) across the entire cohort; the 30-day mortality rate was lower in humoral-ID (n = 5 [4.8%]) than in IC (n = 12 [13.5%]; P = .05) patients. Conclusions: Humoral-ID patients and those with Campylobacter spp BSI were younger and had fewer comorbid conditions, and Campylobacter coli was the most frequent species. Relapse or reinfection was common in humoral-ID patients, particularly those with PID. The antimicrobial resistance in C coli and Campylobacter jejuni represents a clinical concern.
- Open Access
- 3 July 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 85, 103310
Effectiveness and safety of strategies to optimise antimicrobial use in solid organ transplant recipients. Systematic review and meta-analyses
- 3 July 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 85, 103310
Open AccessEffectiveness and safety of strategies to optimise antimicrobial use in solid organ transplant recipients. Systematic review and meta-analyses
- Open Access
- 30 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10550
Could the Adoptive Transfer of Memory Lymphocytes be an Alternative Treatment for Acinetobacter baumannii Infections?
We evaluated the efficacy of the adoptive transfer of memory B, CD4+, and CD8+ T lymphocytes compared with sulbactam and tigecycline in an experimental murine pneumonia model by two multidrug-resistant Acinetobacter baumannii strains, colistin-susceptible AbCS01 and colistin-resistant AbCR17. Pharmacodynamically optimized antimicrobial dosages were administered for 72 h, and intravenous administration of 2 × 106 of each of the memory cells in a single dose 30 min post-infection. Bacterial lung and blood counts and mortality rates were analyzed. Results showed that a single dose of memory B or CD4+ T cells was as effective as sulbactam in terms of bacterial clearance from the lungs and blood compared with the untreated mice or the tigecycline-treated mice inoculated with the AbCS01 strain. In the pneumonia model by AbCR17, a single dose of memory B or CD4+ T cells also reduced the bacterial load in the lungs compared with both antibiotic groups and was more efficacious than tigecycline in terms of blood clearance. Regarding survival, the adoptive transfer of memory B or CD4+ T cells was as effective as three days of sulbactam treatment for both strains. These data suggest that adoptive memory cell transfer could be a new effective treatment of multidrug-resistant A. baumannii infections.
- 30 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10550
Open AccessCould the Adoptive Transfer of Memory Lymphocytes be an Alternative Treatment for Acinetobacter baumannii Infections?
We evaluated the efficacy of the adoptive transfer of memory B, CD4+, and CD8+ T lymphocytes compared with sulbactam and tigecycline in an experimental murine pneumonia model by two multidrug-resistant Acinetobacter baumannii strains, colistin-susceptible AbCS01 and colistin-resistant AbCR17. Pharmacodynamically optimized antimicrobial dosages were administered for 72 h, and intravenous administration of 2 × 106 of each of the memory cells in a single dose 30 min post-infection. Bacterial lung and blood counts and mortality rates were analyzed. Results showed that a single dose of memory B or CD4+ T cells was as effective as sulbactam in terms of bacterial clearance from the lungs and blood compared with the untreated mice or the tigecycline-treated mice inoculated with the AbCS01 strain. In the pneumonia model by AbCR17, a single dose of memory B or CD4+ T cells also reduced the bacterial load in the lungs compared with both antibiotic groups and was more efficacious than tigecycline in terms of blood clearance. Regarding survival, the adoptive transfer of memory B or CD4+ T cells was as effective as three days of sulbactam treatment for both strains. These data suggest that adoptive memory cell transfer could be a new effective treatment of multidrug-resistant A. baumannii infections.
- Open Access
- 3 July 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 146, 107163
COVID-19 in patients with haematologic malignancies: Effect of RNAemia on clinical outcome in vaccinated patients
- 3 July 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 146, 107163
Open AccessCOVID-19 in patients with haematologic malignancies: Effect of RNAemia on clinical outcome in vaccinated patients
- Open Access
- 27 February 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 57, 101871
Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)
- 27 February 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 57, 101871
Open AccessRisk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)
- 5 March 2019
- Published by Elsevier in Medicina Clinica
- Vol. 153 (10) , e55-e56
Nocardiosis diseminada de evolución fatal por Nocardia otitidiscaviarum
- 5 March 2019
- Published by Elsevier in Medicina Clinica
- Vol. 153 (10) , e55-e56
Nocardiosis diseminada de evolución fatal por Nocardia otitidiscaviarum